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Abstract
We recently demonstrated that lack of Furin-processing of the N-cadherin precursor (proNCAD) in highly invasive
melanoma and brain tumor cells results in the cell-surface expression of a nonadhesive protein favoring cell migra-
tion and invasion in vitro. Quantitative polymerase chain reaction analysis of malignant human brain tumor cells
revealed that of all proprotein convertases (PCs) only the levels of Furin and PC5A are modulated, being inversely
(Furin) or directly (PC5A) correlated with brain tumor invasive capacity. Intriguingly, the N-terminal sequence follow-
ing the Furin-activated NCAD site (RQKR↓DW161, mouse nomenclature) reveals a second putative PC-processing
site (RIRSDR↓DK189) located in the first extracellular domain. Cleavage at this site would abolish the adhesive
functions of NCAD because of the loss of the critical Trp161. This was confirmed upon analysis of the fate of
the endogenous prosegment of proNCAD in human malignant glioma cells expressing high levels of Furin and
low levels of PC5A (U343) or high levels of PC5A and negligible Furin levels (U251). Cellular analyses revealed
that Furin is the best activating convertase releasing an ∼17-kDa prosegment, whereas PC5A is the major inacti-
vating enzyme resulting in the secretion of an ∼20-kDa product. Like expression of proNCAD at the cell surface,
cleavage of the NCADmolecule at RIRSDR↓DK189 renders the U251 cancer cells less adhesive to one another and
more migratory. Our work modifies the present view on posttranslational processing and surface expression of
classic cadherins and clarifies how NCAD possesses a range of adhesive potentials and plays a critical role in
tumor progression.
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Introduction
Of the many processes that occur during tumor progression, invasion
and the formation of secondary metastases are the most clinically rel-
evant but the least well understood at the molecular level. Yet, it is
now well established that changes in surface expression of classes of
cell adhesion molecules correlate with malignant transformation
[1,2]. Reduction of intercellular adhesive interactions of tumor cells
is necessary to promote detachment from the main tumor mass and
to alter tumor-host cell interactions necessary for migration and
invasion [3].
Classic cadherins are key cell adhesion molecules in epithelia
that mediate Ca2+-dependent intercellular interactions [4,5] and
are strongly implicated in tumor development [6–8]. It has been
shown that a decrease in cadherin expression is linked to metastatic
tumor behavior [9–12]. Loss of E-cadherin (ECAD) expression
and/or function appears to be necessary for tumor metastasis [1]
and correlates with high tumor grades and poor prognosis [13–
15]. Contrary to ECAD, during the progression of several types
of carcinomas, an up-regulation of neural cadherin (NCAD; also
known as cadherin 2) expression has been shown to occur and
this correlates with increased tumor cell motility and metastasis
[2,3,16,17]. In many cancers, a switch from ECAD to NCAD ac-
companies a highly malignant phenotype [6,13,16,18,19]. How-
ever, other tumors, such as primary gliomas, do not express ECAD
at any stage of development but upregulate NCAD compared to brain
parenchyma [20].
An important determinant of cadherin adhesive activity is the
proteolytic processing of its prosegment, which contains at its C
terminus a long and flexible linker region connecting it to the first
extracellular domain of NCAD [6]. The removal of the prosegment
is needed to expose a critical Trp at the second residue following the
cleavage site (P2′ position) in mature NCAD. This Trp is function-
ally implicated in the homophilic dimerization of cell-surface NCAD
resulting in efficient cell-cell adhesion [21] and the formation of a
complex between the cytosolic catenins and the cytoplasmic tail of
type 1 transmembrane cadherins [22,23]. The prosegment is composed
of 138 amino acids (aa) and lacks the essential structural features re-
quired for adhesion [21]. Following N -glycosylation in the ER and
trafficking to the Golgi, the prodomain is thought to be cleaved in
the trans-Golgi network (TGN) and/or at the cell surface by one or
more members of the proprotein convertase (PC) family. At the C
terminus of their prosegments, classic cadherins contain a consensus
cleavage site for members of the PC family (RXKR↓) [24].
The basic aa-specific mammalian subtilisin-like PCs are a family of
Ca2+-dependent endoproteases, responsible for the activation of pre-
cursor proteins by cleavage at a consensus recognition site (R/K-(2X)-
R/K↓; X = 0–4 aa). The PCs are PC1 (also known as PC1/3), PC2,
Furin, PC4, PC5 [also known as PC5/6A and found in two isoforms,
namely, a soluble PC5A (913 aa) and a longer (1860 aa) membrane-
bound mostly intestinal PC5B isoform], PACE4, and PC7 [24,25].
Whereas PC1 and PC2 are important in the neural and endocrine
pathway, and PC4 only functions in germinal cells, Furin, PACE4,
PC5A, and PC7 have a wide tissue distribution and proteolytically
process precursors in the constitutive secretory pathway [25]. Furin
has catalytic activity primarily in the TGN, at the cell surface and/or
endosomes [26], whereas in many instances PC5A and PACE4 exert
their functions mostly at the cell surface [bound to heparin sulfate
proteoglycans (HSPGs)] or extracellularly [25,27], and PC7 seems to
act exclusively close to the cell surface [28]. Studies have demonstrated
that NCAD [29] and ECAD [30] can be cleaved by Furin to release
their prodomains and expose their critical Trp for adhesion.
What role do PCs play in tumor development? PCs are involved in
the processing and activation of key molecules in tumor progression,
invasion, and metastasis, such as growth factors and membrane-type
metalloproteinases [31–34]. Studies have shown that Furin and
PACE4 are overexpressed in tumor cell lines as well as in primary
human malignancies, and inhibition of these PCs correlates with de-
creased tumorigenesis [31,34–38]. Conversely, cadherins, such as
NCAD, are rendered adhesively active by Furin processing, resulting
in tight cell-cell adhesion and suppression of tumor progression [29].
However, some reports show an opposite effect of Furin and PACE4 in
breast cancer cell invasion [39], Furin in the growth of hepatocellular
carcinoma [40], and a protective effect of PC5 in intestinal tumori-
genesis [41]. Thus, in some cancer models, Furin, PC5, and/or PACE4
may act in similar or opposite fashion.
NCAD is also implicated in physiological invasion processes dur-
ing embryonic development, including neural growth cone extension
[42–45], gastrulation [42,46], and migration of neural crest cells over
large distances [47,48]. It is thus conceivable that differentially pro-
cessed cell-surface NCAD plays an important functional role in these
physiological processes, as also supported by the presence of unprocessed
precursor of N-cadherin (proNCAD) on the surfaces of neurites in the
developing brain [49].
We recently showed that during malignant melanoma transforma-
tion and in highly invasive glioma, e.g., U251 cells, in addition to ma-
ture NCAD, significant amounts of nonadhesive uncleaved proNCAD
are present on the cell surface, promoting tumor cell migration and
invasion [29]. In contrast, in the less invasive U343 cells, most of
proNCAD was processed by endogenous Furin. The present study
extends our original findings and presents a novel role of PC5A in
controlling cell-cell adhesion and invasion through an atypical pro-
cessing of proNCAD into a nonadhesive and pro-invasive form.
Materials and Methods
Cell Culture and Transfections
HeLa cells were purchased from American Type Culture Collec-
tion (Manassas, VA). The human U343 malignant glioma cell line
was generously provided by A. Guha (University of Toronto, Toronto,
Ontario), and the human U251 malignant glioma cell line was pro-
vided by R. Bjervig (University of Bergen, Bergen, Norway). Cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented with
10% FBS (Invitrogen, Burlington, Ontario) and maintained at 37°C
in a humidified atmosphere of 5% CO2. Lipofectamine Plus trans-
fection reagent (Invitrogen) was used to transfect cells.
Constructs
Wild-type (WT) NCAD-myc or mutant proNCAD-myc were
previously described [29]. V5-tagged Furin, PC5A, PC5A-ΔCRD,
PACE4, PACE4-ΔCRD, and PC7 constructs were described else-
where [27,50,51]. An NCAD myc-tagged mutated at S2 (NCAD-II)
was generated using QuickChange II XL Site-DirectedMutagenesis Kit
(Stratagene, La Jolla, CA), according to the manufacturer’s instructions.
Mutagenesis primers are included in Table W1.
Antibodies and Reagents
The following primary antibodies were used for Western immu-
noblot analysis and immunofluorescence: anti-proN [21], mouse
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monoclonal anti-myc (clone 9E10; Sigma-Aldrich, Oakville, ON),
rabbit polyclonal anti-Furin and anti-PC5A (generated in-house),
and fluorescent-conjugated secondary antibodies (Millipore, Billerica,
MA). Fluorescence mounting media (DAKO, Burlington, ON) was
used to mount coverslips on glass slides.
Immunoblot analysis
Protein samples were resolved on a 4% to 15% linear gradient sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE; Bio-
Rad, Mississauga, Ontario), transferred to nitrocellulose, blocked with
5% milk protein, and incubated overnight with primary antibodies at
4°C. Blots were then incubated with HRP-conjugated secondary anti-
bodies (Jackson ImmunoResearch Laboratories, West Grove, PA), and
routine washes were carried out. Blots were developed with the chemi-
luminescence system (Pierce Biotechnology, Rockford, IL). Densito-
metric analysis was carried out using the ImageJ software (National
Institutes of Health, Bethesda, MD). Bands were boxed and back-
ground signal was subtracted from their relative intensities. Intensity
values were normalized to reference values (loading control).
Immunocytochemistry
Cells were plated onto poly-L-lysine–coated coverslips, fixed in 4%
paraformaldehyde, permeabilized in 0.3% Triton X-100 and phosphate-
buffered saline (PBS), and blocked in 5% BSA, 5% goat serum, and
PBS. Cells were then incubated for 1 hour in primary antibody (Ab)
diluted in 1% BSA, 0.02% Triton X-100, and PBS, followed by a
40-minute incubation in fluorescent-conjugated secondary anti-
bodies. Three washes with PBS were performed before fixation, as
well as following each step. Coverslips were mounted and examined
by confocal laser microscopy using the Zeiss LSM 510 microscope
with the Zen image acquisition software and 60× oil immersion
objective. Images were acquired in the same plane of focus be-
tween comparisons.
For live cell staining, cells were plated on coverslips with primary
Ab diluted in medium without serum at 4°C for 1 hour. The cells
were washed with PBS and fixed in 3.7% paraformaldehyde. Follow-
ing three washes with PBS, cells were incubated with fluorescent-
conjugated secondary Ab diluted in 1% BSA, 0.02% Triton X-100,
and PBS for 40 minutes at room temperature and washed, and cover-
slips were mounted and analyzed as above.
Cell Aggregation Assays
Aggregation assays were carried out as previously described [29].
Briefly, monolayer cultures were treated with 2 mM EDTA in PBS for
5 minutes at 37°C. Cells were then washed gently in Hepes-buffered
Ca2+-Mg2+–free Hank’s balanced salt solution supplemented with
1 mM CaCl2 and 1% BSA for 30 minutes at 37°C to dissociate the
monolayer into single cells while leaving cadherins intact on the cell
surface. Following cell dissociation, 5 × 105 cells per well were trans-
ferred to 24-well low-adherent dishes (VWR, Mississauga, Ontario)
and brought up to a final volume of 0.5 ml of Hepes-buffered Ca2+-
Mg2+–free Hank’s balanced salt solution containing 1% BSA with or
without 1 mM Ca2+. The plates were rotated at 80 rpm at 37°C for
observation of aggregate formation during a 40-minute time course.
At t = 0 minute, t = 20 minutes, and t = 40 minutes, 50 μl of the fixed
aggregates was removed, placed on a slide, covered with a coverslip, and
examined by light microscopy. The number of single cells was counted
and the percentage of single cells during the aggregation assay was de-
termined by the index N t/N 0, where N t is the total number of single
cells after a certain incubation time, and N 0 is the total number of
single cells at the initiation of incubation.
Detection of NCAD Proteolytic Products
N-terminal proNCAD segments were detected in the conditioned
medium of cells using the proN Ab. Cells were transiently transfected
with the appropriate construct(s); the conditioned medium was col-
lected 48 hours later and concentrated (Millipore Amicon Filters),
and total protein concentration was determined using a Lowry assay
(Bio-Rad). Conditioned medium (15 μg of protein) was resolved on
a 4% to 15% SDS-PAGE (Bio-Rad), and cleavage products were
detected by Western immunoblot analysis as an ∼17-kDa band
corresponding to cleavage at the S1 consensus site and an ∼20-kDa
band representing cleavage at S2.
Wound-healing Migration Assays
To assess two-dimensional migration of tumor cell lines, we seeded
3 × 105 cells in six-well culture dishes. Before plating in these dishes,
two parallel lines were drawn at the underside of the well with a marker,
serving as fiducial marks for analysis of wound areas. The monolayer
was ∼100% confluent on the day of analysis. The growth medium
was first aspirated and replaced by calcium-free PBS to prevent death
of cells at the edge of the wound by exposure to high calcium concen-
trations. Monolayers were disrupted with a parallel scratch wound
made perpendicular to the marker lines with a fine pipette tip. Migra-
tion into the wound was observed using phase contrast microscopy on
an inverted microscope with 5× objective. Images of random areas of
the wound were sampled for cell counting at regular time intervals of
areas flanking the intersections of the wound and the marker lines. The
number of cells that migrated into the wound was determined by mark-
ing wound edges at t = 0 hour on the underside of the well and count-
ing cells that migrated into the wound at specified time points
appropriate for each cell line using Northern Eclipse software 6.0
(EMPIX Imaging Inc., Mississauga, Ontario).
Small Interfering RNA
Predesigned, small interfering RNA (siRNA) for Furin (#105594
and #112945), PC5A (#17520 and #144223), glyceraldehyde 3-
phosphate dehydrogenase (GAPDH), and Cy3-labeled negative
control #1 were purchased from Ambion (Austin, TX). U343 and
U251 cells were transfected with Furin siRNA (80 nM) and PC5A
siRNA (80 nM), respectively, using Lipofectamine plus reagent. Cells
were used in experiments 3 days after transfection. Furin-targeted
siRNA sequences have been described previously [29].
Reverse Transcriptase–Polymerase Chain Reaction
Reverse transcriptase–polymerase chain reaction (RT-PCR) was
carried out to determine the expression of PCs, and GAPDH was used
as a normalizing control. Real-time PCR was carried out to quantify
PC5A and Furin expression relative to hS14 expression, as previously
described [10]. Primers are listed in Table W1.
Results
The PCs Furin and PC5A Are Differentially Expressed in
Glioma Cells
Classic cadherins are synthesized as inactive precursors, which be-
come functionally mature proteins upon posttranslational modifica-
tions and cleavage. It has been shown that the PC Furin can cleave
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human proECAD at RQRR↓DW156 [30], rendering the molecule
functionally adhesive by exposing Trp156. Similarly, Furin also cleaves
mouse proNCAD at RQRR↓DW161 [21,30] at the C-terminal end of
the prodomain, thereby exposing the critical Trp161 (Figure 1B).
In the present work, we concentrated on the various forms of
NCAD found in tumors. Accordingly, we evaluated the mRNA
expression levels of the relevant constitutive basic aa-specific PCs,
namely, Furin, PC5A, PACE4, and PC7 in a panel of various tumor
cells to determine whether differences in levels of these enzymes
might underlie the mechanism(s) leading to different forms of cell-
surface NCAD. Because only 45% of the highly invasive glioma cells,
compared to 70% of metastatic melanoma cells, expressed unprocessed
proNCAD at the cell surface owing to the low expression of Furin [29],
this suggested that there may be additional mechanisms associated with
malignant glioma cell invasion. RT-PCR analyses revealed similar levels
of PC7 in U343 and U251 cells, and expression of PACE4 was not
detected in either cell line (Figure 1A). Interestingly, the mRNA levels
of Furin were low in highly invasive U251 cells, relative to the less
invasive U343 cells. In contrast, PC5 mRNA expression was high in
U251 cells relative to U343 cells (Figure 1A). Quantitative RT-PCR
(qRT-PCR) analyses showed that Furin is 36-fold more expressed than
PC5A in U343 cells, whereas PC5A is 4-fold more expressed than
Furin in U251 cells (Figure 1B). The relatively low Furin expression
in U251 cells could be a plausible explanation for the previously ob-
served presence of proNCAD at the surface of these cells [29]. The
contrasting expression of PC5A was intriguing, especially because it
was demonstrated that proECAD was processed in the Furin-deficient
LoVo cells, indicating that another convertase could process cadherins
[30], including proNCAD. Upon scrutiny of the mouse proNCAD
sequence, we identified a second putative S2 site at RIRSDR↓DK189
(conserved in human proNCAD) following the primary Furin-cleavable
S1 site at RQKR↓DW161 (Figure 1B). Should cleavage occur at S2,
the ensuing NCAD-ΔN28 product lacking the N-terminal 28 aa of
NCAD would have lost the critical Trp161 and likely be nonadhesive.
Using an in-house–generated Ab against the prodomain of NCAD [29],
we were surprised to find that the endogenous prodomain of NCAD
in U343 and U251 cells exhibits a different molecular size. Thus, in
U343 and U251 cells, it predominantly migrates on SDS-PAGE as
an ∼17-kDa or an ∼20-kDa protein, respectively (Figure 1C ), sug-
gesting differential cleavage by endogenous proteases in these cells.
To identify the cognate convertase at the S2 site (generating the
∼20-kDa prodomain), we first showed that incubation of cells with
the general PC inhibitor decanoyl-RVKR-chloromethylketone (dec-
RVKR-cmk) [25] completely abrogates both S1 and S2 cleavages, sug-
gesting that both are accomplished by one or more PCs (Figure 1C ).
To identify which PC is responsible for the generation of the
∼20-kDa prodomain following cleavage at S2, we expressed each
PC and proNCAD in HeLa cells (that lack endogenous PC5A
[52]). As control, we showed that PC5A and Furin can similarly cleave
proPDGF-A [53] in these cells (not shown). The data showed that
of all PCs, PC5A is the only convertase capable of generating the
∼20-kDa product from both endogenous and overexpressed proNCAD
(Figure 1D), whereas Furin (Figure 1E) and PACE4 (Figure 1F) do
not cleave proNCAD at the S2 site, and PC7 does not seem to cleave
at either site, as the level of the ∼17-kDa product does not change
upon expression of this enzyme (Figure 1G ).
To unambiguously identify the important residues governing cleav-
age at the S2 site, we mutated the putative P1 residue Arg187 to Ala
generating the sequence to RIRSDA↓DK189. Co-expression of this
R187A mutant with PC5A in HeLa cells, lacking both endogenous
NCAD [29] and PC5A expression [52], resulted in the generation of
the ∼17-kDa product but not the ∼20-kDa product containing at its
C terminus the first 28 aa of mature NCAD, confirming that the
PC5A-mediated production of NCAD-ΔN28 by cleavage at position
S2 is lost (Figure 1H ).
Cell-surface PC5A Cleaves NCAD at S2 in Glioma
and HeLa Cells
Proteolytic processing of proteins by PCs takes place in the TGN,
cell surface, or endosomes [25,26]. To probe the subcellular location(s)
where proNCAD processing by PC5A into NCAD-ΔN28 resulting in
an ∼20-kDa prodomain takes place, we expressed in HeLa cells a trun-
cated form of PC5A (PC5A-ΔCRD) lacking the C-terminal cysteine-
rich domain (CRD) [27,50]. The results showed that co-expression of
proNCAD and PC5A-ΔCRD substantially reduced PC5A-mediated
proteolysis at S2 but did not abolish it (Figure 2A). This indicates that
in large part cleavage at S2 takes place at the plasma membrane, as sup-
ported by previous studies showing that the CRD of PC5A mediates
cell-surface anchoring of the enzyme through interactions with HSPGs
[27,50]. To further support this conclusion, we demonstrated that in-
cubations with the PC cell-surface inhibitor d6R [54,55] only partially
abolished the proNCAD processing (Figure 2A), whereas dec-RVKR-
cmk [54,55], a cell permeable PC inhibitor, completely blocked pro-
cessing (Figure 1, C and D). Thus, proNCAD is processed by PC5A
both at the cell surface and intracellularly, either at the TGN or
following endocytosis.
We then looked at the localization of PC5A in transfected HeLa
cells (Figure 2B). Herein, the protein localized to the cell surface, as
assayed by immunofluorescence under nonpermeabilizing conditions
(Figure 2B, upper panel); however upon heparin treatment, PC5A
was no longer located at the cell surface (Figure 2B, middle panel), be-
fitting its cell-surface binding to HSPGs [27,50]. In addition, PC5A-
ΔCRD did not localize to the cell surface of HeLa cells (Figure 2B,
lower panel ), as also reported for COS-1 cells [27]. Thus, HSPG-bound
PC5A localizes to the cell surface [27,50] where it presumably cleaves
most of proNCAD at the S2 site.
We next investigated the localization of endogenous PC5A by
immunofluorescence and detected substantial levels of the enzyme
at the cell surface of U251 cells but very low levels at the surface of
U343 cells (Figure 2C , upper panel ). As we observed upon PC5A
overexpression in HeLa cells (Figure 2B), endogenous PC5A immuno-
reactivity was not detectable at the cell surface when heparin was added
to the medium of glioma cells (Figure 2C , middle panel ). Further-
more, as previously reported in COS-1 cells [27], immunoreactivity
of the prosegment of PC5A can also be detected at the cell surface of
U251 cells (but not U343 cells) with an Ab specific for the prosegment
of PC5A [50]. This suggests that a fraction of PC5A is found in an
inactive form noncovalently bound to its inhibitory prosegment at
the surface of U251 cells, as reported for COS-1 cells [27]. Finally, un-
der permeabilizing conditions, we note that in U251 cells endogenous
immunoreactive PC5A and its prosegment mostly localize to a peri-
nuclear compartment, likely the TGN (Figure 2C , bottom panel ), sim-
ilar to its intracellular localization in brain neurons [56]. We deduce
that in this compartment a fraction of PC5A is still in an inactive form
bound to its inhibitory prosegment. Thus, similar to COS-1 cells [27],
we interpret the above data, combined with those in the literature de-
scribing the zymogen activation of PC5A [25,27], to mean that auto-
catalytic cleavage of proPC5A occurs in two steps, a first one in the ER
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Figure 1. Furin and PC5A PCs mediate cleavage of NCAD at S1 and S2, respectively. (A) Semi–qRT-PCR was carried out to look at
expression of PCs, and results show differential expression of Furin and PC5A (the major PC5A isoform is used here) in U343 and
U251 cells. GAPDH expression served as reference. (B) Schematic diagram of precursor NCAD protein with the S1 cleavage site and
the putative S2. Tryptophan at position 161, necessary for adhesion, is in bold and underlined. Real-time PCR was carried out to quantify
Furin and PC5A expression. The results are plotted as number of mRNA messages/106 hS14 messages and show contrasting Furin and
PC5A expression patterns in U343 and U251 cells. HeLa cells were used as a positive control for Furin and a negative control for PC5A.
(C) U251 and U343 cells were transfected with WT NCAD vector or empty vector and incubated in the presence or absence of dec-
RVKR-cmk. The conditioned medium was concentrated (20×) and run on a 15% gel, and NCAD cleavage peptides were detected with
the proN Ab. Cleavage products with molecular masses of ∼17 kDa and ∼20 kDa corresponded to processing of NCAD at S1 and S2,
respectively. NCAD was predominantly cleaved at S2 in U251 cells and exclusively at S1 in U343 cells. (D) HeLa cells were transiently
transfected with NCAD +/− full-length PC5A or empty vector, and cells were incubated in the absence or presence of dec-RVKR-cmk.
Cleavage products were detected in the conditioned medium as in C. (E–G) Transfections as in D were carried out. Furin was used in E,
PACE4 was used in F, and PC7 was used in G. (H) HeLa cells were transiently transfected with PC5A and either WT NCAD or its R187A
mutant (at the P1 position) position, and cleavage products in the conditioned medium were detected as above.
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where processing of its prosegment initially takes place at the first
position, and then at the cell surface where the autocatalytic activa-
tion by cleavage at the second site in the prosegment finally releases
the active form of PC5A [27]. On the basis of our present study, this
general model seems to apply to two different glioma cell lines, as well
as HeLa cells.
Residues Surrounding S2 Dictate the Efficiency of
PC5A-mediated Processing of proNCAD
Residues adjacent to the consensus cleavage site (both at P2–P8 and
P1′, PC2′) are known to influence the proteolytic efficiency of PCs
through specific interactions with S and S′ subsites within the con-
vertases, respectively [25,57–59]. Therefore, we carried out point
mutations at the P1, P4, and P6 Arg of mouse proNCAD, corre-
sponding to aa 187, 184, and 182, respectively. The P1 mutation
R187A abolished PC5A-mediated proNCAD (Figure 3A), yielding
an S2 cleavage-resistant cadherin (NCAD-II). The P4 substitution of
R184A substantially diminished the proteolytic activity of PC5A at S2,
without abolishing it, whereas the P6 mutant R182A only moderately
reduced the proteolytic activity of PC5A at S2 (Figure 3A). However,
the double P4, P6 substitution R184A and R182A completely abol-
ished PC5A-mediated proteolysis at S2. These results demonstrate that
the basic residues at the P1, P4, and P6 positions are important for
PC5A-mediated proNCAD processing at S2, with the P1 Arg187 being
the most critical, followed by the P4 and then P6 Arg. Thus, as seen
with all other basic aa-specific convertases [25], at least two basic aa are
necessary for proNCAD processing by PC5A at S2, namely, the critical
P1 Arg and the presence of either a P4 or P6 Arg.
Proteins targeted to the plasma membrane get N - and/or O-
glycosylated, and such posttranslational modifications are known to
be important for cadherin function [60]. We tested the impact of
glycosylation of residues in the vicinity of the S2 site. Our results
demonstrate that N -glycosylation at the P3′ Asn190 at the consensus
Asn190-X-Ser sequence partially inhibits PC5A-mediated cleavage
Figure 2. Processing of NCAD by PC5A and immunocytochemical localization of PC5A and its prosegment in U251 and U343 cells.
(A) Transfections were done as in Figure 1 except that HeLa cells were transfected with either full-length PC5A (here, we only used
the major PC5A isoform throughout [25]) or PC5A-ΔCRD. PC5A with a deleted CRD (PC5A-ΔCRD) cleaved NCAD to a much lesser extent
compared to full-length PC5A. (B) Immunocytochemistry was carried out to look at PC5A localization in transfected HeLa cells both
under nonpermeabilizing and permeabilizing conditions, as described [27]. PC5A C-terminally tagged with a V5 epitope was cloned
in the pIRES2-EGFP vector, and hence, cells were probed with a monoclonal Ab–V5 [27]. Cells were transfected with either full-length
PC5A, in the absence or presence of heparin and staining was carried out under nonpermeabilizing conditions to detect cell-surface
localization. Cells were also transfected with PC5A-ΔCRD and stained under permeabilizing conditions to identify intracellular localiza-
tion. (C) Immunocytochemistry of U251 and U343 cells demonstrate localization of endogenous PC5A and its inhibitory prosegment at the
cell surface and intracellularly in a perinuclear site. An NT-PC5A Ab detected total PC5A protein, and an Ab against the PC5A prosegment
(proPC5A) detected only the prosegment containing proteins [27,50]. Staining was carried out under nonpermeabilizing conditions with
or without heparin or under permeabilizing conditions. Bar, 10 μm.
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at S2, because the N190Q mutant is better processed (Figure 3C ).
However, N120Q, S185A, and S192A have no effect on processing
(Figure 3C). We conclude that N -glycosylation at the P3′ site reduces
the extent of the PC5A-mediated processing of proNCAD at the S2
position. We also surmise that no O-glycosylation occurs in proximity
to the S2 site, which would otherwise have reduced the extent of
processing, as observed in multiple precursor proteins [61].
Cleavage of NCAD by Furin or PC5A Determines the
Extent of Cellular Migration
To test the functional significance of proNCAD processing, we
carried out gain- and loss-of-function experiments, where U251 cells
were stably transfected with Furin (Figures 4 and 5), and U343 cells
(Figure 4) were stably transfected with PC5A or a catalytically in-
active PC5A mutant lacking the second autocatalytic site (PC5A-
R84A; [50]), resulting in its inability to process its inhibitory prosegment
that remains noncovalently bound to the mature enzyme keeping it
in an inactive state [27]. Our results demonstrate that compared to
control transfections, overexpression of Furin in U251 cells resulted
in an ∼65% decrease in the number of migrated cells at 12 hours in
a wound-healing assay (Figure 4A) and these cells aggregated to a much
greater extent compared to control ones (Figure 4B). In contrast, over-
expression of PC5A in U343 cells resulted in a significant increase in
the number of migrated cells compared to cells transfected with the
control plasmid, and these cells formed very few small aggregates com-
pared to control cells (Figure 4B). As expected, these effects were not
seen with cells transfected with the inactive PC5A-R84A (Figure 4, A
and B). Thus, the changes observed in migratory behavior are consis-
tent with those that modulate cell aggregation.
We also carried out knockdown experiments using siRNAs spe-
cific for PC5A or Furin. Cells were successfully transfected with
siRNAs (Table W1), and RT-PCR demonstrated an ∼80% reduc-
tion of Furin mRNA levels in U343 cells and PC5A mRNA levels
in U251 cells (Figure W1, B and C ). Furin or PC5A siRNAs did not
affect PC7 or NCAD mRNA levels (Figure W1B). In addition,
GAPDH levels were not affected by Furin or PC5A siRNA but were
reduced by a GAPDH-specific siRNA (Figure W1B). By immuno-
cytochemistry, we also noted a decrease in Furin and PC5A levels
in U343 and U251 cells, respectively, but there was no reduction in
tubulin, nestin, or β-catenin expression (Figure W1D). Our siRNA
results show that compared to control siRNA, knockdown of PC5A in
U251 cells resulted in a significant decrease in cell migration (Figure 4A)
and a corresponding increase in cell aggregation (Figure 4B). The effect
on migration was somewhat less pronounced than that observed with
Furin-transfected cells (Figure 4A, left panel). This can be explained by
the fact that U251 cells transfected with PC5A-specific siRNAwould still
express proNCAD on their surface because of low endogenous Furin
expression [29]. Knockdown of Furin in U343 cells resulted in a sub-
stantial increase in cell migration (Figure 4A) and decrease in cell aggre-
gation (Figure 4B). Altogether, these results demonstrate that Furin
expression appears to inhibit glioma cell migration, whereas PC5A
expression promotes it.
To demonstrate the functional importance of proNCAD process-
ing by PC5A or Furin, we used our previously reported NCAD-I
mutant lacking the S1 site [29] and engineered an R187A mutant
where the second S2 cleavage site was abolished (NCAD-II) but leav-
ing the consensus S1 site RQKR↓DW161 intact (Figure 5A). We then
carried out a series of transient transfections in U343 cells, which
express low levels of PC5A, with either WT NCAD, NCAD-I, or
NCAD-II, alone or in combination with Furin or PC5A. Compared to
nontransfected cells, there is a small decrease in migration (Figure 5B)
and a small increase in aggregation (Figure 5C) in cells transfected with
WT NCAD. This was expected because U343 cells express high levels
of Furin needed to process NCAD at the consensus S1 site. A 15%
further decrease in migration and increase in aggregation was observed
in cells transfected with WT NCAD and Furin (Figure 5, B and C).
Importantly, when cells were transfected with NCAD-II and PC5A,
the increase in migration detected with WT NCAD and PC5A was
not observed (Figure 5B).
Discussion
Morphogenesis and tissue homeostasis depend on the assembly and
regulation of cohesive intercellular junctions. Such key processes are
finely regulated by calcium-dependent type 1 transmembrane proteins
localized to intercellular junctions. Among these, the classic cadherins
are the major cell adhesive molecules that modulate the architecture
of intercellular junctions. The mature cell-surface localized forms of
cadherins exert their cell-cell cohesion by homophilic interactions be-
tween adjacent cells. Such binding requires the homodimerization of
their extracellular domains (ECs), arranged as five tandem structural seg-
ments named EC1 to EC5 (Figure 5A). The primary adhesive interface
involves the mutual insertion of a conserved Trp at the second position
from the N terminus of mature cadherins (Trp161 of mouse NCAD)
into the hydrophobic pocket on EC1 domain (aa 160–267) of the
apposing protein from neighboring cells [21]. Indeed, mutating Trp161
into Ala abolishes NCAD-mediated adhesion [62]. Another important
structural element regulating the homophilic interaction of NCAD
involves a salt bridge between Glu248 in EC1 and the free amine of
Figure 3. Critical residues in the PC5A processing of NCAD.
(A) HeLa cells were co-transfected with cDNAs coding for PC5A
and either WT NCAD or its P1, P4, and P6 mutants. A control with
no PC5A expression was included. Twenty-four hours after trans-
fection, the media were analyzed by Western blot using the proN
Ab. The migration positions of the NCAD prodomain with apparent
molecular masses of ∼17 and 20 kDa are emphasized. (B) In a
similar fashion, the PC5A processing of NCAD mutants at specific
Asn or Ser residues is shown.
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the N-terminal Asp160 of mature NCAD [63]. Thus, the loss of the
NH2-Asp-Trp161 dipeptide at the N terminus of NCAD would be ex-
pected to prevent NCAD homodimerization at the intercellular surface.
Unstable intercellular adhesion contributes to cellular detachment
and metastatic dissemination of tumor cells. Among the various
membrane-bound cadherins, NCAD is a key cell adhesion protein
both in normal physiology and during tumorigenesis. It is thought
that the strength of the intercellular adhesion is governed by the level
of cell-surface NCAD and by the prevalence of its dimeric forms
[64]. Up until recently, it was also believed that the N-terminal pro-
domain in classic cadherins is completely removed by an endoprotease
within the late Golgi following association of the catenins, resulting in a
mature adhesively competent molecule at the cell surface [4,22,23,65].
However, we recently showed that proNCAD can escape proper
Figure 4. Migration and aggregation of U251 and U343 cells depends on the expression of Furin and PC5A. (A) A wound-healing assay
was carried out with mock-transfected cells, U251-Furin cells, U343-PC5A cells, or U343 cells transfected with the PC5A-R84A catalytic
mutant. In addition, this assay was carried out with U251 cells transfected with PC5A siRNA and with U343 cells transfected with Furin
siRNA.Migrationwasmonitored over a 24-hour period, and results were quantified as number ofmigrated cells at 12 hours. (B) An adhesion
assay was carried out with the transfected glioma cells and siRNA-transfected cells. Cell aggregation was monitored over a 40-minute time
period, and results were quantified as % single cells over time. Values are means ± SEM.
Neoplasia Vol. 14, No. 10, 2012 Opposite Roles of Furin and PC5A Maret et al. 887
cleavage and be expressed as a precursor protein at the cell surface of
aggressive brain tumor cells, as well as malignant melanoma cell lines
and other human carcinoma cells, likely because of the low expression
levels of its processing enzyme Furin [29]. Owing to the development
of a specific NCAD prodomain Ab, this was the first reported case of
persistence of the prodomain at intercellular surfaces.
Herein, we report that during malignant transformation, proNCAD
undergoes an alternative proteolytic processing by another convertase
PC5A. Thus, we demonstrate that in highly invasive brain tumor cells
NCAD can be processed by PC5A at an inactivating S2 cleavage site
RIRSDR↓DK189. This PC-modulated mechanism results in a mixture
of NCADmolecular forms at the cell surface with both proNCAD and
NCAD-ΔN28 (Figure 6), functionally enhancing cellular migration and
invasion (Figures 4 and 5). The enhanced levels of proNCAD at the
cell surface [29] and cleavage at the second S2 site (this work) appear
to be because of down-regulation of Furin and up-regulation of PC5A,
respectively (Figures 1 and 6). The resulting NCAD-ΔN28, lacking the
first 28 aa at the N terminus, would lose the critical N-terminal NH2-
Asp-Trp161 sequence and is likely to be nonadhesive (Figures 4 and 5).
Classic cadherins can exist in a weakly adhesive monomeric form or
as dimers, which are strongly adhesive [66,67]. We speculate that
proNCAD and inactive NCAD-ΔN28 may disrupt NCAD arrays
emanating from juxtaposed cells by intercalating between lateral dimers
(Figure 6). It has been shown that the prodomain of ECAD prevents
Figure 5. Proprotein processing of NCAD by Furin or PC5A determines the extent of cellular migration. (A) Schematic diagram of pre-
cursor NCAD protein with the endogenous second cleavage site and the engineered mutant nonfunctional site (NCAD-II). Tryptophan at
position 2, necessary for adhesion, is in bold. U343 cells were transiently transfected with WT NCAD, proN(Ncad-I), or NCAD mutated at
the second cleavage site (NCAD-II), with or without Furin or PC5A, and wound-healing (B) and adhesion assays (C) were carried out to
determine the functional effects of NCAD processing by Furin or PC5A at the consensus or the second cleavage site.
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dimer formation and that dominant negative forms of cadherins with
extracellular domain deletions prevent cadherin self-association. It is
conceivable that by altering cadherin composition at the cell surface,
the adhesive strength of nascent cell-cell contacts may be regulated,
allowing for fine-tuning of malignant intercellular connections.
Would it be possible for proNCAD to be cleaved by Furin intra-
cellularly and then inactivated by PC5A at the cell surface in cells
expressing both enzymes? Sequential cleavage of a precursor protein
by PCs has been previously demonstrated. The precursor of bone mor-
phogenic protein 4 undergoes serial cleavage at two sites in its prodo-
main, and differential use of the upstream site determines the activity of
the mature protein partially through regulating protein stability [68].
Perhaps in a proportion of highly aggressive tumor cells, NCAD gets
cleaved sequentially by Furin and PC5A or proNCAD could be cleaved
directly by PC5A at the cell surface. Preliminary results revealed that
the PC5A-inactivated NCAD-ΔN28 is much less stable at the cell sur-
face than mature active NCAD (not shown). Thus, the inactivation
of NCAD results in the loss of the critical Trp161 for adhesion and
decreased levels of cell-surface NCAD.
Mechanistically, we demonstrated that by determining the site of
NCAD processing the convertases Furin and PC5A have opposing
effects on the extent of intercellular adhesion and cellular motility
(Figures 4 and 5). Perhaps a decrease in PC5A expression is an early
event necessary for cells to associate with their neighbors and stop
invading. It is conceivable that although PC5A cleavage of NCAD
seems to be critical for invasion, the cleavage of other substrates by this
convertase is also likely to be important for invasion or other traits
acquired by highly malignant cells. Indeed, it has been shown that
PCs are important for the activation of other cancer-related substrates.
For example, in human head and neck squamous cell carcinoma and
astrocytoma cells, Furin has been shown to be important for activation
of substrates important in tumorigenesis, such as membrane type 1
matrix metalloproteinase, transforming growth factor–β, insulin-like
growth factor–1 receptor, and vascular endothelial growth factor C
[35,69,70]. Processing of the insulin-like growth factor–1 receptor by
PCs including Furin and PC5A, as well as processing of proPDGF-A
mainly by Furin, has also been shown to be important in human colon
carcinoma cells [31,53].
In general, inhibition of the convertases has been shown to decrease
growth and tumorigenicity, as this group of proteases is known to pro-
cess substrates important for tumor malignancy and cellular invasion
[31,32,35,69]. However, recent studies demonstrated that PCs may,
in some instances, be protective against tumorigenesis, cell migration,
and metastases [40,41,71]. Our studies demonstrate that the effect of
PC processing on tumor malignancy appears to be more complex than
previously thought. Moreover, this complexity is certainly much greater
in vivo compared to cells grown in vitro. The inactivation of a PC
substrate at the plasma membrane is not unprecedented. Indeed,
pro-endothelial lipase is retained at the cell-surface through HSPGs
and was demonstrated to be inactivated by cleavage with full-length
PACE4 and/or PC5A [72] but not by either of these PCs lacking their
HSPG-binding CRDs, [27,50]. In our study, we demonstrate a second
instance where the CRD of PC5A is necessary for cell-surface cleavage
leading to inactivation of the NCAD likely in association with cell-
surface HSPGs.
Down-regulation of the level of cell adhesion molecules and/or
their dimerization represents one way by which cells reduce intercellular
adhesions. In many carcinomas, epithelial junctions are no longer de-
tectable because of the loss of close cell-cell contacts. This is an impor-
tant step during the epithelial-to-mesenchymal transition (EMT) that is
believed to occur during carcinogenesis [73]. Loss of cell-cell adhesion
is followed by other important phenotypic changes during EMT such
Figure 6. Proposed schematic diagram depicting surface cadherin expression during tumor progression. When progressing from the
premalignant to malignant stage, cells with a high proportion of proN and inactivated NCAD have a higher migratory and invasive
potential compared to cells with a lower proportion of proNCAD and inactivated NCAD-ΔN28. This corresponds to higher levels of
PC5A and lower levels of Furin and lower levels of PC5A and higher levels of Furin, respectively.
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as loss of cell polarity and the acquisition of migratory and invasive
properties. The loss of ECAD is considered to be a critical event in
EMT, as ECAD repressors are capable of functioning as full EMT
inducers in different cell types [74]. This is accompanied by an up-
regulation of NCAD in many types of carcinomas and the switch from
ECAD to NCAD correlates with induced cellular motility [2,3,16].
It is believed that because of disruption of adhesion junctions, loss of
ECAD allows malignant cells to detach from the epithelium and invade
host tissue, whereas up-regulation of NCAD expression facilitates inva-
sion of tumor cells by mediating adhesion of malignant cells to stromal
or endothelial cells rather than epithelial cells [75].
Alternatively, as we have demonstrated, intercellular adhesion
could be modulated by surface expression of a nonadhesive proNCAD
[29], or NCAD-ΔN28 (this work). Thus, our results should lead to the
revision of the current model of cadherin posttranslational processing
and surface expression [3,16,18,76,77]. We propose that in later stages
of tumor progression nonadhesive surface proNCAD and functionally
inactivated NCAD-ΔN28 determine the degree of cell invasiveness and
metastasis and shed light on the stages of malignancy during tumor pro-
gression. Consequently, the switch from ECAD to NCAD during
EMT is in fact a switch to a mixture of NCAD molecules where only
a certain proportion is functionally adhesive. In brain tumor cells,
which do not undergo an ECAD-to-NCAD shift, the switch from
mature NCAD to nonadhesive NCAD-ΔN28 molecules mediates
detachment from the main tumor mass and migration over extensive
distances in our in vitro assay (Figures 4 and 5). Preliminary data in
an intracranial xenograft mouse model show that prevention of the
formation of NCAD-ΔN28 results in a less aggressive phenotype
compared to WT (in preparation).
We speculate that differential expression of PCs may be a common
mechanism in many types of tumors to regulate cellular motility and
perhaps other malignant traits and is perhaps central in developmental
programs. In addition, precursor forms of other types of cadherins at
the cell surface may play a similar role in tumor cell motility. Accord-
ingly, alignment of the processing sites of various cell adhesion mole-
cules (Figure W2) revealed that the seminal observation reported here
may be more general than previously appreciated. Indeed, the Furin
dibasic cleavage site and the alternative PC5A-mediated monobasic
processing site characterized herein for proNCAD are found to be
conserved in a number of cadherin family members including ECAD,
P-cadherin, and cadherin-11 that play pivotal roles in cancer develop-
ment and progression [76,78,79]. It remains to be defined if PC5A
also mediates these inactivation processes and whether such a mecha-
nism regulates the functions of these adhesion molecules both physiolog-
ically and/or pathologically. In that context, mining the ONCOMINE
cancer gene expression database (http://www.oncomine.org) revealed
that PC5A expression was significantly reduced in most tumors [41]
but was actually upregulated in 3 of 10 tumor types including pancre-
atic ductal adenocarcinoma, glioblastoma multiforme, and anaplastic
oligoastrocytoma/oligodendroglioma (Figure W3). On the basis of
our present work, it is possible that in these latter types of tumors
PC5A would also promote cancer metastasis.
Malignant primary brain tumors are extremely complex and hetero-
geneous microenvironments, characterized by subpopulations of highly
invasive cells that infiltrate the normal brain parenchyma, often sig-
nificant distances from the primary tumor mass [80]. Unlike most
carcinomas, these tumors do not enter blood vessels and form metas-
tases in distant organs. Instead, fatality is because of “micro-metastasis”
within the brain, resulting in destruction of regions essential for survival
of the patient [81]. Uncontrollable invasion leads to failure of treatment
modalities such as radiotherapy and chemotherapy and recurrence
following radical resection.
The mechanism proposed herein sheds light on putative novel
treatment strategies with the potential to attenuate extensive infiltra-
tion of the brain parenchyma by malignant tumor cells and reduce
the frequency of fatal recurrences following tumor resection. Further-
more, in cancers such as malignant melanoma and malignant glial
tumors [29], characterization of the cell-surface forms of NCAD
may serve as a prognostic tool for staging and progression of the dis-
ease. Our work may potentially lead to treatment strategies to control
the metastatic spread of malignant brain carcinomas, through the
development of specific PC5 inhibitors.
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Table W1. Primers Used for PCR Experiments.
Target Sequence (5′ to 3′)
hFurin (+)* ATCCCAGGAATGAGTTGTC
(−)† CTCACCCTGTCCTATAATCG
hPC5A (+) TGACCACTCTTCAGAGAATGGATAC
(−) GAGATACCCACTAGGGCAGC
hPC7 (+) CATCATTGTCTTCACAGCCACC
(−) ATGACTCATCCCCGACATCC
hPACE4 (+) GGTGGACGCAGAAGCTCTCGTTG
(−) AGGCTCCATTCTTTCAACTTCC
hGAPDH (+) CGAGATCCCTCCAAAATCAA
(−) CATGAGTCCTTCCACGATACCAA
mNCAD-R182A (+) CAGAATCGCGTCTGATAGAGATAAAAACC
(−) CTCTATCAGACGCGATTCTGACAAGCTC
mNCAD-S184A (+) CAGAATCAGGGCTGATAGAGATAAAAACC
(−) CTCTATCAGCCCTGATTCTGACAAGCTC
mNCAD-R187A (+) CAGGTCTGATGCAGATAAAAACCTTTCCC
(−) GGTTTTTATCTGCATCAGACCTGATTCTG
mNCAD-N120Q (+) GCTGTACAGCTGAGCCGGGAG
(−) CCCGGCTCAGCTGTACAGCTACCTGCC
mNCAD-N190Q (+) GAGATAAACAGCTTTCCCTGAGATACAGCG
(−) ATCTCAGGGAAAGCTGTTTATCTCTATCAGAC
NCAD-S192A (+) GAGATAAAAACCTTGCCCTGAGATACAG
(−) CTGTATCTCAGGGCAAGGTTTTTATCTC
*(+), Forward primer.
†(−), Reverse primer.
Figure W1. Furin siRNA and PC5A siRNA results in 80% knockdown of these convertases in U343 and U251 cells, respectively. Knock-
down experiments using siRNAs specific for PC5A or Furin were carried out in glioma cells. Cells were successfully transfected with
siRNA (A), and RT-PCR demonstrated an 80% reduction of Furin mRNA levels in U343 cells and PC5A mRNA levels in U251 cells (B and
C). Furin or PC5A siRNA did not affect PC7 or NCAD mRNA levels (B). In addition, GAPDH levels were not affected by Furin or PC5A
siRNA but were reduced by a GAPDH-specific siRNA (B). Immunocytochemistry also demonstrated a reduction in Furin and PC5A levels
in U343 and U251 cells, respectively (D), but there was no reduction in tubulin, nestin, or β-catenin expression (D). Bar, 10 μm.
Figure W2. Alignment of various cadherins around the proNCAD
Furin-mediated and PC5A-mediated processing sites. The red ar-
rows point to the predicted cleavage sites by Furin (likely activating
S1 site) and PC5A (likely inactivating S2 site) in multiple cadherins.
Figure W3. Regulation of PC5A expression in various cancers. Data sets were retrieved from ONCOMINE (a cancer microarray database
and integrated data-mining platform; http://www.oncomine.org) with a threshold of P < .0001. PC5A expression value in tumors was
log2 transformed and normalized to that in the adjacent normal tissue. Notice that in 3 (caption in red) of 10 tumors PC5A expression
was higher than that in adjacent normal tissue.
